Harit Thongwitokomarn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Harit Thongwitokomarn has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Kanokkarn Pinyopornpanish
Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University , Chiang Mai
1 shared publication - Kanokporn Pinyopornpanish
Department of Family Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai
1 shared publication - Phichayut Phinyo
Department of Biomedical Informatics and Clinical Epidemiology (BioCE), Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
1 shared publication - Romanee Chaiwarith
Faculty of Medicine and Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand
1 shared publication - Sutina Laimangkorn
Department of Family Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai
1 shared publication - Wannada Laisuan
Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
1 shared publication
Latest Publications
- Open Access
- 30 October 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (11)
Clinical Benefit of Adjunctive Rituximab in Anti–Interferon-Gamma Autoantibody-Associated Immunodeficiency: A Retrospective Self-Controlled Cohort Study
Background: Antimicrobial therapy is the cornerstone of treatment for anti–interferon-gamma (IFN-γ) autoantibody-associated immunodeficiency (AOID), but persistent or relapsing infections remain challenging. We evaluated outcomes associated with adjunctive rituximab in patients with AOID. Methods: We conducted a retrospective self-controlled cohort study of adult patients with AOID treated at a tertiary care hospital in Northern Thailand between January 2019 and December 2024. Each patient contributed data from 2 treatment periods: antimicrobial therapy alone and with adjunctive rituximab. Clinical and laboratory outcomes were compared over 3-month observation windows. Results: Among 14 patients with AOID, the mean age was 61.00 ± 8.84 years, and 6 patients (42.86%) were male. Nontuberculous mycobacteria (NTM) infection was present in all patients. Rapidly growing mycobacteria infections were the predominant NTM infections in both treatment periods, occurring in 13 patients (92.86%). Compared with the antimicrobial-only period, adjunctive rituximab was associated with a significantly higher likelihood of successful antimicrobial de-escalation (adjusted odds ratio, 5.38; 95% confidence interval [CI], 1.16–25.00; P = .032). Rituximab exposure was also associated with a greater reduction in absolute lymphocyte count (adjusted β, −379 cells/µL; 95% CI, −725 to −33; P = .032) and a modest increase in alkaline phosphatase (adjusted β, 32.8 U/L; 95% CI, 8.7–56.9; P = .008). No rituximab-associated infusion reactions, hypersensitivity reactions, severe infections related to immunosuppression, or deaths were observed. Conclusions: Adjunctive rituximab was associated with a higher likelihood of successful antimicrobial de-escalation without major short-term safety concerns. Further prospective evaluation is warranted.
- 30 October 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (11)
Open AccessClinical Benefit of Adjunctive Rituximab in Anti–Interferon-Gamma Autoantibody-Associated Immunodeficiency: A Retrospective Self-Controlled Cohort Study
Background: Antimicrobial therapy is the cornerstone of treatment for anti–interferon-gamma (IFN-γ) autoantibody-associated immunodeficiency (AOID), but persistent or relapsing infections remain challenging. We evaluated outcomes associated with adjunctive rituximab in patients with AOID. Methods: We conducted a retrospective self-controlled cohort study of adult patients with AOID treated at a tertiary care hospital in Northern Thailand between January 2019 and December 2024. Each patient contributed data from 2 treatment periods: antimicrobial therapy alone and with adjunctive rituximab. Clinical and laboratory outcomes were compared over 3-month observation windows. Results: Among 14 patients with AOID, the mean age was 61.00 ± 8.84 years, and 6 patients (42.86%) were male. Nontuberculous mycobacteria (NTM) infection was present in all patients. Rapidly growing mycobacteria infections were the predominant NTM infections in both treatment periods, occurring in 13 patients (92.86%). Compared with the antimicrobial-only period, adjunctive rituximab was associated with a significantly higher likelihood of successful antimicrobial de-escalation (adjusted odds ratio, 5.38; 95% confidence interval [CI], 1.16–25.00; P = .032). Rituximab exposure was also associated with a greater reduction in absolute lymphocyte count (adjusted β, −379 cells/µL; 95% CI, −725 to −33; P = .032) and a modest increase in alkaline phosphatase (adjusted β, 32.8 U/L; 95% CI, 8.7–56.9; P = .008). No rituximab-associated infusion reactions, hypersensitivity reactions, severe infections related to immunosuppression, or deaths were observed. Conclusions: Adjunctive rituximab was associated with a higher likelihood of successful antimicrobial de-escalation without major short-term safety concerns. Further prospective evaluation is warranted.